Spinal Muscular Atrophy Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

PRESS RELEASE
Published March 16, 2023

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 18+ key pharma and biotech companies are working on 20+ pipeline drugs in the Spinal Muscular Atrophy therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Spinal Muscular Atrophy therapeutics market is anticipated to evolve immensely in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.

Spinal Muscular Atrophy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Spinal Muscular Atrophy Market.

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Spinal Muscular Atrophy Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Spinal Muscular Atrophy and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Spinal Muscular Atrophy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Treatment of SMA is quite challenging however, in an overall perspective, recent and extensive research and development activities being conducted for the development of novel drugs, increased understanding of the related comorbidities, along with the upcoming pipeline drugs, is expected to create a lucrative environment for the growth of SMA treatment market. Key players such as Cytokinetics, Scholar Rock, Roche, and others are involved in developing treatments for SMA.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Spinal muscular atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

– Oral
– Parenteral
– Intravenous
– Subcutaneous
– Topical

Molecule Type
Products have been categorized under various Molecule types, such as

– Monoclonal Antibody
– Peptides
– Polymer
– Small molecule
– Gene therapy

Spinal Muscular Atrophy Therapeutics Landscape

With the approval of three therapies for SMA (Spinraza, Evrysdi and Zolgensma (gene therapy)), some of the unmet needs for the treatment of SMA were fulfilled. Moreover, the management of SMA is also based on supportive and multidisciplinary care with a focus on reducing complications and improving quality of life. The current market holds alternatives for symptomatic relief. However, approaches for SMA management also focus on nutrition, respiratory care assessment, respiratory muscle weakness, orthopedic care, rehabilitation, and a few off-label medications.

To further improve the treatment scenario, several major pharma and biotech giants are developing therapies for Spinal muscular atrophy. Currently, Scholar Rock is leading the therapeutics market with its Spinal muscular atrophy drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Spinal Muscular Atrophy (SMA) Therapeutics Market Include:

– Alcyone Therapeutics
– Amniotics
– Amylon Therapeutics
– AndroScience Corporation
– Astellas Pharma
– Aurimed Pharma
– Biogen
– Biohaven Pharmaceuticals
– CANbridge Pharmaceuticals Inc.
– Catalyst Pharmaceuticals
– Exicure
– Hanugen Theraputics
– Hoffmann-La Roche
– NMD Pharma
– Scholar Rock
– Voyager Therapeutics
And Many Others

Spinal Muscular Atrophy (SMA) Emerging and Marketed Drugs Covered in the Report Include:

– Apitegromab: Scholar Rock
– ACTX-401: Alcyone Therapeutics
– Reldesemtiv: Cytokinetics
– GYM329: Roche
– Spinraza (nusinersen): Biogen
– Zolgensma: Novartis
– Evrysdi: Hoffmann-La Roche
And Many More

Explore More About the Emerging Drugs and Key Companies: Spinal Muscular Atrophy Pipeline Development Activities

Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Spinal Muscular Atrophy Current Treatment Patterns
4. Spinal Muscular Atrophy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Spinal Muscular Atrophy Late-Stage Products (Phase-III)
7. Spinal Muscular Atrophy Mid-Stage Products (Phase-II)
8. Spinal Muscular Atrophy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Spinal Muscular Atrophy Discontinued Products
13. Spinal Muscular Atrophy Product Profiles
14. Key Companies in the Spinal Muscular Atrophy Market
15. Key Products in the Spinal Muscular Atrophy Therapeutics Segment
16. Dormant and Discontinued Products
17. Spinal Muscular Atrophy Unmet Needs
18. Spinal Muscular Atrophy Future Perspectives
19. Spinal Muscular Atrophy Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Spinal Muscular Atrophy Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Newsmantraa